Search results
Results from the WOW.Com Content Network
On Sept. 25, BioAge's stock proceeded with its IPO, which raised gross proceeds of $238.3 million. Before the IPO, it had raised $321 million via several rounds of funding with private investors ...
Biotech stocks are making headlines on Friday as two companies join the public market via initial public offerings (IPOs) today. Source: Shutterstock Let’s dive into the first of the new biotech ...
This year has seen more than its share of successful IPOs – and some giant flops. The extremes should have been expected, in a year with a record number of new public offerings. The second ...
Later that year in December 2022, Roivant and Pfizer announced [24] their third partnership to create a new Vant [25] focused on developing TL1A drug candidates for inflammatory and fibrotic diseases. As of February 2023, Roivant's reported market cap was over $6 billion. [26]
Founded in 2003 and headquartered in South San Francisco, California, Portola Pharmaceuticals is a member of the NASDAQ Biotechnology Index. In May 2020, Alexion Pharmaceuticals and Portola announced that they had entered into a definitive merger agreement for Alexion to acquire Portola.
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases.
Some 108 companies conducted their IPO in 2023 and raised $19.4 billion, according to Renaissance Capital. Those figures rose markedly from the 2022 doldrums of 71 IPOs and just $7.7 billion raised.
In July 2015, Soon-Shiong initiated an IPO for NantKwest (formerly ConkWest) that represented the highest value biotech IPO in history, at a market value of $2.6 billion. [50] In April 2016, the Los Angeles Times reported that Soon-Shiong received a pay package in 2015 from NantKwest worth almost $148 million, making him one of the highest paid ...